The present disclosure generally relates to the field of medicine. The present invention more specifically relates to a pharmaceutical composition comprising the combination of (i) at least one biocompatible nanoparticle comprising, or consisting in, at least one natural compound which is an inhibitor of a human CYP enzyme, the longest dimension of said nanoparticle being of at least 4 nm and less than 100 nm, and of (ii) at least one compound of interest, typically at least one pharmaceutical compound, to be administered to a subject in need of such at least one compound of interest, wherein the combination of the at least one biocompatible nanoparticle and of the at least one compound of interest potentiates the at least one compound of interest’s bioavailability.The at least one biocompatible nanoparticle is to be administered to the subject separately from the at least one compound of interest (preferably before), typically with an interval of between at least about 5 minutes (preferably more than about 5 minutes) and about 72 hours.本發明概言之係關於醫學領域。本發明更具體而言係關於包含以下之組合之醫藥組合物:(i)至少一種生物相容奈米粒子,其包括或存在有至少一種係人類CYP酶抑制劑之天然化合物,該奈米粒子之最長尺寸為至少4nm且小於100nm,及(ii)至少一種所關注化合物、通常至少一種醫藥化合物,該醫藥組合物欲投與需要該至少一種所關注化合物之個體,其中該至少一種生物相容奈米粒子與該至少一種所關注化合物之該組合加強該至少一種所關注化合物之生物利用度。該至少一種生物相容奈米粒子係與該至少一種所關注化合物分開(較佳在之前)投與該個體,通常間隔介於至少約5分鐘(較佳超過約5分鐘)與約72小時之間。
